Dr. Pablo Guzman is a cardiologist in Fort Lauderdale, Florida where he is on staff at Holy Cross Hospital. He received his medical degree from University of Puerto Rico School of Medicine and his Cardiology Fellowship at The Johns Hopkins Hospital where he then spent the first part of his career continuing his basic science and clinical research along with his clinical duties. His CV includes over 25 papers published in peer reviewed journals and more than 15 abstracts. He is a Fellow of the American College of Cardiology and practiced for more than 30 years. Dr. Guzman is well experienced in basic and clinical research, having participated in many clinical trials. He is also the acting Chief Medical Officer of Variant Pharmaceuticals, a Specialty Pharma company developing treatments for kidney diseases.

“It is with great pleasure we welcome Dr. Pablo Guzman to our Scientific Advisory Board to join our other distinguished members. Dr. Guzman not only brings a wealth of clinical experience and expertise in cardiovascular disease, but has been actively involved in all stages of translational research from bench to bedside”, said Timothy Dixon, President and CEO.

“I am fascinated by the rapid progress Mr. Dixon, and the team at TSOI, have accomplished in developing and patenting pterostilbene based therapeutics in the area of oncology” said Dr. Guzman “It is very rare to see a company combine natural-based approaches, in areas such as nutraceuticals, with hard science. I look forward to helping expand some of the Company’s technologies into the cardiovascular space, as well as assist in accelerating clinical translation of the existing programs.”

The Company was recently granted US Patent #9,682,047 which covers uses of the blueberry derived natural ingredient pterostilbene for augmenting efficacy of cancer immunotherapy. TSOI also has an application with the U.S. Patent and Trademark Office for means of augmenting circulating endogenous stem cells through administration of an effective amount of pterostilbene or derivatives thereof.

And yesterday we announced our third Pterostilbene patent for the Synergistic Inhibition of Glioma Using Pterostilbene of which Dr. Guzman is co-inventor. Additionally, the Company has an Investigational New Drug IND application that was filed with the FDA for its cancer stem cell targeting immunotherapeutic, StemVacs.

“The process of developing new therapeutics is complicated and often associated with unforeseen obstacles. I am very enthusiastic to work alongside a medical pioneer like Dr. Guzman, who will greatly assist in our seamless transition into a clinical stage company”, said Dr. Thomas Ichim, Board Member of TSOI and CEO of Emvolio, Inc,.

About Therapeutic Solutions International, Inc.Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is www.therapeuticsolutionsint.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.